Feb. 3 at 1:06 PM
$AXSM 02/02/2026 (MT Newswires) -- Axsome Therapeutics' (AXSM) AXS-05 drug candidate for Alzheimer's disease agitation is set for a "strong" launch, with the potential to reach at least
$1.4 billion in peak sales, RBC Capital Markets said in a Monday note.
The brokerage said that the Prescription Drug User Fee Act date for AXS-05 is April 30 and a potential approval could drive the company's stock above
$200.
Analysts said AXS-05's profile should appeal to physicians and enable it to outperform the Rexulti drug. RBC estimates about
$212 million in sales in fiscal 2027 and
$352 million in fiscal 2028.
The rest of Axsome's pipeline, including Sunosi, Symbravo, AXS-12, and AXS-14, has yet to receive full market attention despite being in late-stage development.
The investment firm noted that consensus estimates for AXS-05 remain below other Alzheimer's disease agitation products, suggesting the opportunity is not yet fully reflected in the stock. (continued in the comments)
